#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16404	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2340	854.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1846	1846	T	1053	T,C,A	1050,2,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	16404	16S	1529	1529	99.93	16S.l6.c17.ctg.1	2340	854.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1580	1580	C	1009	C,A	1008,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28348	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3992	885.5	0	.	n	.	0	T695C	SNP	695	695	T	1257	1257	C	1035	C,T,G	1030,2,2	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28348	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3992	885.5	0	.	n	.	0	G1337A	SNP	1337	1337	G	1899	1899	A	1169	A,G	1168,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28348	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3992	885.5	0	.	n	.	0	T1971C	SNP	1971	1971	T	2533	2533	C	989	C	989	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28348	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3992	885.5	1	SNP	n	A2045G	0	.	.	2045	2045	A	2607	2607	A	985	A,T,C	983,1,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	28348	23S	2890	2890	99.9	23S.l15.c4.ctg.1	3992	885.5	1	SNP	n	C2597T	0	.	.	2597	2597	C	3159	3159	C	969	C	969	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	2170	folP	852	852	98.24	folP.l15.c17.ctg.1	2133	127.1	0	.	p	.	0	R7Q	NONSYN	19	21	CGG	635	637	CAG	134;136;137	C;A;G	134;136;137	.	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	2170	folP	852	852	98.24	folP.l15.c17.ctg.1	2133	127.1	0	.	p	.	0	E12K	NONSYN	34	36	GAA	650	652	AAA	161;162;164	A,G;A;A	160,1;162;164	.	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	2170	folP	852	852	98.24	folP.l15.c17.ctg.1	2133	127.1	0	.	p	.	0	F31L	NONSYN	91	93	TTT	707	709	TTG	194;194;198	T;T,C;G	194;193,1;198	.	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	2170	folP	852	852	98.24	folP.l15.c17.ctg.1	2133	127.1	0	.	p	.	0	S68P	NONSYN	202	204	TCG	818	820	CCG	227;229;230	C,T;C;G	225,2;229;230	.	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	2170	folP	852	852	98.24	folP.l15.c17.ctg.1	2133	127.1	0	.	p	.	0	F72Y	NONSYN	214	216	TTC	830	832	TAT	236;235;236	T,A;A,T;T,C	235,1;234,1;235,1	.	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	2170	folP	852	852	98.24	folP.l15.c17.ctg.1	2133	127.1	0	.	p	.	0	P74S	NONSYN	220	222	CCG	836	838	TCG	230;229;227	T,C;C,T;G	229,1;228,1;227	.	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	2170	folP	852	852	98.24	folP.l15.c17.ctg.1	2133	127.1	0	.	p	.	0	A89V	NONSYN	265	267	GCG	881	883	GTG	199;200;199	G;T,C;G	199;199,1;199	.	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	2170	folP	852	852	98.24	folP.l15.c17.ctg.1	2133	127.1	0	.	p	.	0	E151K	NONSYN	451	453	GAA	1067	1069	AAA	220;219;218	A;A;A	220;219;218	.	.
folP.WHO_W_01420c	folP.WHO_W_01420c	1	1	539	2170	folP	852	852	98.24	folP.l15.c17.ctg.1	2133	127.1	1	SNP	p	R228S	1	.	.	682	684	AGC	1298	1300	AGC	229;227;225	A,C;G,T;C,T	228,1;226,1;224,1	folP.WHO_W_01420c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5754	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3993	180.0	1	SNP	p	S91F	1	.	.	271	273	TTC	971	973	TTC	215;216;216	T,G;T,C;C	214,1;215,1;216	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5754	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3993	180.0	1	SNP	p	D95G	1	.	.	283	285	GGC	983	985	GGC	214;216;215	G,A;G,T;C,T	213,1;215,1;214,1	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5754	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3993	180.0	1	SNP	p	G95N	0	.	.	283	285	GGC	983	985	GGC	214;216;215	G,A;G,T;C,T	213,1;215,1;214,1	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	2066	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1886	136.7	1	SNP	p	G45D	0	.	.	133	135	GGC	763	765	GGC	231;232;231	G;G;C	231;232;231	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1106	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c17.ctg.1	1516	91.1	0	.	n	.	0	A197.	DEL	197	197	A	838	838	A	205	A,T	204,1	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5354	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3408	196.0	1	SNP	p	D86N	0	.	.	256	258	GAC	815	817	GAC	227;226;226	G;A;C	227;226;226	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5354	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3408	196.0	1	SNP	p	R87I	0	.	.	259	261	CGT	818	820	CGT	226;228;229	C,A;G;T	225,1;228;229	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5354	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3408	196.0	1	SNP	p	S87R	1	.	.	259	261	CGT	818	820	CGT	226;228;229	C,A;G;T	225,1;228;229	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5354	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3408	196.0	1	SNP	p	R87W	0	.	.	259	261	CGT	818	820	CGT	226;228;229	C,A;G;T	225,1;228;229	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5354	parC	2304	2304	100.0	parC.l15.c4.ctg.1	3408	196.0	1	SNP	p	S88P	0	.	.	262	264	TCC	821	823	TCC	229;227;230	T,C;C;C	228,1;227;230	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4556	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3078	184.6	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1741	1743	GGC	256;254;251	G;G,A;C,T	256;253,1;250,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.3.001	penA.3.001	1	1	27	4270	penA	1752	1752	99.94	penA.l15.c4.ctg.1	2838	187.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1446	1448	GCA	236;234;236	G;C,T,G;A	236;232,1,1;236	penA.3.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.3.001	penA.3.001	1	1	27	4270	penA	1752	1752	99.94	penA.l15.c4.ctg.1	2838	187.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1449	1451	ATC	236;233;234	A,T;T;C	235,1;233;234	penA.3.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.3.001	penA.3.001	1	1	27	4270	penA	1752	1752	99.94	penA.l15.c4.ctg.1	2838	187.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1461	1463	GTG	236;239;234	G;T;G	236;239;234	penA.3.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.3.001	penA.3.001	1	1	27	4270	penA	1752	1752	99.94	penA.l15.c4.ctg.1	2838	187.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1461	1463	GTG	236;239;234	G;T;G	236;239;234	penA.3.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.3.001	penA.3.001	1	1	27	4270	penA	1752	1752	99.94	penA.l15.c4.ctg.1	2838	187.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1965	1967	ACC	240;241;243	A;C,T;C	240;240,1;243	penA.3.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.3.001	penA.3.001	1	1	27	4270	penA	1752	1752	99.94	penA.l15.c4.ctg.1	2838	187.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2142	2144	GGC	191;191;192	G,C;G;C	190,1;191;192	penA.3.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.3.001	penA.3.001	1	1	27	4270	penA	1752	1752	99.94	penA.l15.c4.ctg.1	2838	187.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2151	2153	GGC	199;201;200	G;G,A;C,T,G	199;200,1;198,1,1	penA.3.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.3.001	penA.3.001	1	1	27	4270	penA	1752	1752	99.94	penA.l15.c4.ctg.1	2838	187.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2169	2171	CCG	216;218;213	C,T;C;G,C,T	214,2;218;210,2,1	penA.3.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	5996	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3702	202.3	1	SNP	p	L421P	1	L421P	NONSYN	1261	1263	CTG	1906	1908	CCG	242;241;238	C;C;G	242;241;238	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2676	porA	1146	1146	99.91	porA.l6.c17.ctg.1	2192	151.9	0	.	p	.	0	M83fs	FSHIFT	247	247	A	769	769	C	212	C	212	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	342	porB1a	984	222	90.09	porB1a.l6.c17.ctg.1	303	28.5	0	.	p	.	0	V258L	NONSYN	772	774	GTA	13	15	TTA	22;27;27	T;T;A	22;27;27	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	342	porB1a	984	222	90.09	porB1a.l6.c17.ctg.1	303	28.5	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	58	60	CAT	55;55;55	C;A;T	55;55;55	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	342	porB1a	984	222	90.09	porB1a.l6.c17.ctg.1	303	28.5	0	.	p	.	0	D274S	NONSYN	820	822	GAT	61	63	AGT	55;55;55	A;G;T	55;55;55	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	342	porB1a	984	222	90.09	porB1a.l6.c17.ctg.1	303	28.5	0	.	p	.	0	D276N	NONSYN	826	828	GAT	67	69	AAC	55;55;55	A;A;C	55;55;55	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	342	porB1a	984	222	90.09	porB1a.l6.c17.ctg.1	303	28.5	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	70	72	TAC	55;55;55	T;A;C	55;55;55	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	342	porB1a	984	222	90.09	porB1a.l6.c17.ctg.1	303	28.5	0	.	p	.	0	R307A	NONSYN	919	921	AGA	160	162	GCA	2;2;3	G;C;A	2;2;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	342	porB1a	984	222	90.09	porB1a.l6.c17.ctg.1	303	28.5	0	.	p	.	0	T311A	NONSYN	931	933	ACA	172	174	GCA	3;3;3	G;C;A	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	342	porB1a	984	222	90.09	porB1a.l6.c17.ctg.1	303	28.5	0	.	p	.	0	E312D	NONSYN	934	936	GAA	175	177	GAC	3;3;3	G;A;C	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	342	porB1a	984	222	90.09	porB1a.l6.c17.ctg.1	303	28.5	0	.	p	.	0	F314I	NONSYN	940	942	TTC	181	183	ATC	5;5;5	A;T;C	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	342	porB1a	984	222	90.09	porB1a.l6.c17.ctg.1	303	28.5	0	.	p	.	0	A316S	NONSYN	946	948	GCG	187	189	TCG	5;5;5	T;C;G	5;5;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	342	porB1a	984	222	90.09	porB1a.l6.c17.ctg.1	303	28.5	0	.	p	.	0	V318A	NONSYN	952	954	GTC	193	195	GCC	5;5;6	G;C;C	5;5;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	342	porB1a	984	222	90.09	porB1a.l6.c17.ctg.1	303	28.5	0	.	p	.	0	G319S	NONSYN	955	957	GGC	196	198	AGC	6;6;6	A;G;C	6;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	342	porB1a	984	222	90.09	porB1a.l6.c17.ctg.1	303	28.5	0	.	p	.	0	G320A	NONSYN	958	960	GGT	199	201	GCC	6;6;6	G;C;C	6;6;6	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	342	porB1a	984	222	90.09	porB1a.l6.c17.ctg.1	303	28.5	0	.	p	.	0	G322V	NONSYN	964	966	GGT	205	207	GTT	6;7;7	G;T;T	6;7;7	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	512	342	porB1a	984	93	94.62	porB1a.l6.c17.ctg.4	166	73.5	0	.	p	.	0	M18T	NONSYN	52	54	ATG	124	126	ACG	83;82;75	A;C;G	83;82;75	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3106	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1835	208.8	0	.	p	.	0	N38E	NONSYN	112	114	AAT	546	548	GAA	309;313;313	G;A;A	309;313;313	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3106	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1835	208.8	0	.	p	.	0	N134D	NONSYN	400	402	AAT	834	836	GAT	293;289;290	G,A;A;T	292,1;289;290	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3106	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1835	208.8	0	.	p	.	0	P175S	NONSYN	523	525	CCA	957	959	TCA	275;276;275	T;C;A	275;276;275	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3106	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1835	208.8	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1086	1088	GTC	246;245;242	G;T;C	246;245;242	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3106	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1835	208.8	0	.	p	.	0	F222S	NONSYN	664	666	TTT	1098	1100	TCT	234;234;237	T;C;T,C	234;234;235,2	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3106	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1835	208.8	0	.	p	.	0	D297N	NONSYN	889	891	GAC	1323	1325	AAC	210;208;208	A;A;C	209;207;208	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3106	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1835	208.8	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1416	1418	GCA	233;234;235	G;C;A	233;234;235	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3106	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1835	208.8	1	SNP	p	G120K	1	.	.	358	360	AAG	792	794	AAG	258;259;262	A;A;G	258;259;262	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3106	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1835	208.8	1	SNP	p	D121N	0	.	.	361	363	GAC	795	797	GAC	264;266;266	G,C;A;C,A	262,2;266;265,1	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	3106	porB1b	1047	1047	99.14	porB1b.l15.c17.ctg.1	1835	208.8	1	SNP	p	A121D	1	.	.	361	363	GAC	795	797	GAC	264;266;266	G,C;A;C,A	262,2;266;265,1	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10692	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5496	243.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1598	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1593	125.2	1	SNP	p	V57M	1	.	.	169	171	ATG	766	768	ATG	278;281;284	A;T;G	278;281;284	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
